Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

10. Februar 2015 16:00 ET | Quelle: ZS Pharma

ZS Pharma Appoints Martin Babler to Board of Directors

COPPELL, Texas, Feb. 10, 2015 (GLOBE NEWSWIRE) -- ZS Pharma (Nasdaq:ZSPH), a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today...
06. Januar 2015 08:00 ET | Quelle: ZS Pharma

ZS Pharma to Present at J.P. Morgan Healthcare Conference

COPPELL, Texas, Jan. 6, 2015 (GLOBE NEWSWIRE) -- ZS Pharma (Nasdaq:ZSPH), a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today...
21. November 2014 12:00 ET | Quelle: ZS Pharma

ZS Pharma Announces Publication of Results From Phase 3 Study of ZS-9 in Patients With Hyperkalemia in the New England Journal of Medicine

COPPELL, Texas, Nov. 21, 2014 (GLOBE NEWSWIRE) -- ZS Pharma (Nasdaq:ZSPH), a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today...
19. November 2014 18:46 ET | Quelle: ZS Pharma

ZS Pharma Hosts and Webcasts Investor Event

COPPELL, Texas, Nov. 19, 2014 (GLOBE NEWSWIRE) -- ZS Pharma (Nasdaq:ZSPH), a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today...
17. November 2014 08:00 ET | Quelle: ZS Pharma

ZS Pharma Presents Positive Results From HARMONIZE (ZS004), a Second Phase 3 Clinical Trial of ZS-9 in Patients With Hyperkalemia, at the American Heart Association Scientific Meeting and Announces Simultaneous Publication of Results in JAMA

COPPELL, Texas, Nov. 17, 2014 (GLOBE NEWSWIRE) -- ZS Pharma (Nasdaq:ZSPH), a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today...
10. November 2014 16:00 ET | Quelle: ZS Pharma

ZS Pharma Reports Third Quarter 2014 Financial Results and Provides ZS-9 Program Update

COPPELL, Texas, Nov. 10, 2014 (GLOBE NEWSWIRE) -- ZS Pharma, Inc. (Nasdaq:ZSPH), a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders,...
06. November 2014 08:00 ET | Quelle: ZS Pharma

ZS Pharma Announces Late Breaking Presentation of Phase 3 HARMONIZE (ZS004) Trial Results in Patients With Hyperkalemia at AHA Annual Meeting

COPPELL, Texas, Nov. 6, 2014 (GLOBE NEWSWIRE) -- ZS Pharma (Nasdaq:ZSPH), a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today...
30. Oktober 2014 16:00 ET | Quelle: ZS Pharma

ZS Pharma Announces Multiple Presentations From ZS003, a Phase 3 Trial of ZS-9, at the American Society of Nephrology Annual Meeting

COPPELL, Texas, Oct. 30, 2014 (GLOBE NEWSWIRE) -- ZS Pharma (Nasdaq:ZSPH), a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today...
28. Oktober 2014 16:00 ET | Quelle: ZS Pharma

ZS Pharma to Present at the Credit Suisse Annual Healthcare Conference

COPPELL, Texas, Oct. 28, 2014 (GLOBE NEWSWIRE) -- ZS Pharma (Nasdaq:ZSPH), a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today...
23. September 2014 16:00 ET | Quelle: ZS Pharma

ZS Pharma Announces Positive Top-Line Results From HARMONIZE (ZS004), a Second Phase 3 Clinical Trial of ZS-9 in Patients With Hyperkalemia

COPPELL, Texas, Sept. 23, 2014 (GLOBE NEWSWIRE) -- ZS Pharma (Nasdaq:ZSPH), a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today...

Vorherige Seite

Nächste Seite